Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Center Clinical Trial to Investigate the Safety and Tolerability of Single and Multiple Oral Doses of DNL747 in Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Center Clinical Trial to Investigate the Safety and Tolerability of Single and Multiple Oral Doses of DNL747 in Healthy Subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DNL-747 (Primary)
  • Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Denali Therapeutics Inc

Most Recent Events

  • 19 Nov 2018 Results presented in a Denali Therapeutics media release.
  • 11 Nov 2018 New trial record
  • 08 Nov 2018 According to a Denali Therapeutics media release, data from this trial will be presented at the Denali 2018 R&D Day on December 10, 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top